The Oncology Institute Reports 41.2% Revenue Growth to $147.4 Million in Q1 2026

The Oncology Institute, Inc. reported significant financial performance for the first quarter of 2026, with total operating revenue reaching $147.4 million, a 41.2% increase from $104.4 million in the same period of 2025. This growth was primarily driven by a 77.6% surge in specialty pharmacy revenue, which amounted to $87.5 million, and an 11.3% increase in patient services revenue, totaling $59.1 million. The company recorded a net loss of $2.5 million, a substantial improvement compared to a net loss of $19.6 million in the prior year, resulting in a net loss per share of $0.02, down from $0.21.

In terms of operational metrics, The Oncology Institute expanded its reach, operating 65 community-based oncology practices across five states and managing a network of 275 providers. The company reported a total of 116 oncologists and mid-level professionals, serving approximately 2 million patients under value-based agreements. The increase in patient services revenue was attributed to a 54% rise in capitated revenue, although fee-for-service revenue saw a 10% decline. The specialty pharmacy segment benefited from a 102.8% increase in prescription fills, despite a decrease in average revenue per fill.

The company's total operating expenses for the quarter were $154 million, up from $114.3 million in the previous year, largely due to increased direct costs associated with patient services and specialty pharmacy operations. Selling, general, and administrative expenses also rose by 11.2% to $28.2 million, reflecting investments in operational infrastructure and technology. The company’s cash and cash equivalents at the end of the quarter stood at $30.3 million, down from $33.6 million at the end of 2025, with net cash used in operating activities decreasing to $2.2 million from $5 million in the prior year.

Strategically, The Oncology Institute continues to focus on enhancing its service offerings and operational efficiencies. The company has entered into a profit-sharing agreement with Helios CR, Inc. for its clinical trials segment, which is expected to streamline operations and improve financial performance. The company is also exploring the implementation of artificial intelligence to enhance operational processes, including prior authorization and denial automation.

Looking ahead, The Oncology Institute anticipates sufficient liquidity to fund its operations for at least the next year, although it acknowledges potential challenges in generating necessary funds in the future. The company remains committed to its mission of providing high-quality, value-based cancer care while navigating the complexities of the healthcare landscape.